Last reviewed · How we verify
Clopidogrel Tapering
Clopidogrel tapering is a dosing strategy that gradually reduces clopidogrel exposure after dual antiplatelet therapy to assess safety and efficacy of de-escalation in cardiovascular patients.
Clopidogrel tapering is a dosing strategy that gradually reduces clopidogrel exposure after dual antiplatelet therapy to assess safety and efficacy of de-escalation in cardiovascular patients. Used for De-escalation strategy in acute coronary syndrome post-percutaneous coronary intervention, Assessment of dual antiplatelet therapy duration optimization.
At a glance
| Generic name | Clopidogrel Tapering |
|---|---|
| Also known as | Plavix |
| Sponsor | Deutsches Herzzentrum Muenchen |
| Drug class | P2Y12 receptor antagonist (thienopyridine) |
| Target | P2Y12 platelet receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a thienopyridine P2Y12 platelet receptor antagonist that irreversibly inhibits platelet aggregation. Tapering protocols investigate whether gradual dose reduction or discontinuation maintains antithrombotic benefit while reducing bleeding risk in patients who have completed an initial intensive dual antiplatelet therapy period, particularly after acute coronary syndrome or percutaneous coronary intervention.
Approved indications
- De-escalation strategy in acute coronary syndrome post-percutaneous coronary intervention
- Assessment of dual antiplatelet therapy duration optimization
Common side effects
- Stent thrombosis
- Recurrent myocardial infarction
- Bleeding
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |